These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7850539)

  • 1. Functional morbidity of hyperthermic isolated regional perfusion of the extremities.
    Olieman AF; Schraffordt Koops H; Geertzen JH; Kingma H; Hoekstra HJ; Oldhoff J
    Ann Surg Oncol; 1994 Sep; 1(5):382-8. PubMed ID: 7850539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP).
    Knorr C; Melling N; Goehl J; Drachsler T; Hohenberger W; Meyer T
    Int J Hyperthermia; 2008 Aug; 24(5):409-14. PubMed ID: 18608587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
    Vrouenraets BC; in't Veld GJ; Nieweg OE; van Slooten GW; van Dongen JA; Kroon BB
    Eur J Surg Oncol; 1999 Oct; 25(5):503-8. PubMed ID: 10529261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival.
    Bryant PJ; Balderson GA; Mead P; Egerton WS
    World J Surg; 1995; 19(3):363-8. PubMed ID: 7638989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone.
    Edwards MJ; Soong SJ; Boddie AW; Balch CM; McBride CM
    Arch Surg; 1990 Mar; 125(3):317-21. PubMed ID: 2306179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
    Thompson JF; Gianoutsos MP
    World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.
    Hafström L; Rudenstam CM; Blomquist E; Ingvar C; Jönsson PE; Lagerlöf B; Lindholm C; Ringborg U; Westman G; Ostrup L
    J Clin Oncol; 1991 Dec; 9(12):2091-4. PubMed ID: 1960549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Technique and results of hyperthermic perfusion of the extremity in melanoma patients].
    Omlor G; Bahmer F; Meessen S; Zang D; Feifel G; Zaun H
    Langenbecks Arch Chir; 1993; 378(1):21-5. PubMed ID: 8437498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
    Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
    Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic perfusion with chemotherapy for melanoma of the extremities.
    Ghussen F; Krüger I; Smalley RV; Groth W
    World J Surg; 1989; 13(5):598-602. PubMed ID: 2815804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.
    Vrouenraets BC; Klaase JM; Kroon BB; van Geel BN; Eggermont AM; Franklin HR
    Arch Surg; 1995 Jan; 130(1):43-7. PubMed ID: 7802575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
    Koops HS; Vaglini M; Suciu S; Kroon BB; Thompson JF; Göhl J; Eggermont AM; Di Filippo F; Krementz ET; Ruiter D; Lejeune FJ
    J Clin Oncol; 1998 Sep; 16(9):2906-12. PubMed ID: 9738557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities.
    Klaase JM; Kroon BB; van Geel BN; Eggermont AM; Franklin HR; Hart GA
    Am J Surg; 1994 Jun; 167(6):618-20. PubMed ID: 8209941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
    Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H
    Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma.
    Vrouenraets BC; Kroon BB; Klaase JM; Nieweg OE; van Slooten GW; van Dongen JA
    Melanoma Res; 1995 Dec; 5(6):425-31. PubMed ID: 8589617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
    Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
    Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.